Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avapritinib DDI with Midazolam in GIST and Solid Tumors
NCT04908176Phase 1Completed
- Sponsor
- Blueprint Medicines
- Start
- Aug 2022
- Primary completion
- Mar 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of avapritinib in gastrointestinal stromal tumor (GIST), solid tumor and glioma, sponsored by Blueprint Medicines. Primary endpoints: Maximum Plasma Concentration of Midazolam at Day 18, Time of Maximum Plasma Concentration of Midazolam at Day 18 and 1 more. Started Aug 2022; status: completed.
02
Drugs
avapritinib
03
Conditions
gastrointestinal stromal tumor (GIST)solid tumorglioma
Beyond the preview
Go deeper on NCT04908176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04908176.